Ottawa Eye News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ottawa eye. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ottawa Eye Today - Breaking & Trending Today

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology

Clinically meaningful difference between visual outcomes of LUMEVOQ®-treated patients and untreated patients Regulatory News: GenSight Biologics . ....

Wills Eye Hospital , United States , France General , United Kingdom , Midi Pyrées , Thomas Jefferson University , City Of , Julie Saltzmann , Neringa Jurkute , Magali Taiel , Catherine Vignal Clermont , Alfredoa Sadun , Nancyj Newman , Los Angeles , Operativa Compless Clinica Neurologica , Jean Fran , Gensight Biologics , Patrick Yu , Valerie Biousse , Valerio Carelli , Adama Debusk , Claudia Priglinger , Rustum Karanjia , Thomas Klopstock , Michel Roux , Robertc Sergott ,

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that ....

Wills Eye Hospital , United States , France General , United Kingdom , Thomas Jefferson University , City Of , Comunidad Autonoma De Cataluna , Neringa Jurkute , Magali Taiel , Clinica Neurologica , Markl Moster , Laure Blouin , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Francescom Bandello , Los Angeles , Stephanie Leruez , Gensight Biologics , Valerio Carelli , Patrick Yu , Lorena Castillo Campillo , James Palmer , Rustum Karanjia , Catherine Vignal Clermont , Jeanene Timberlake ,

GenSight Biologics Announces Publication of Results from LUMEVOQ RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology

Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology,
Ophthalmology
® gene therapy in
ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper , published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset”, is the second peer-reviewed article based on Phase III clinical trial data to document comparable bilateral improvement in visual outcomes from a unilateral injection of a gene therapy. ....

New York , United States , Wills Eye Hospital , France General , United Kingdom , Thomas Jefferson University , City Of , University Hospital , Emory University School Of Medicine , Magali Taiel , Clinica Neurologica , Piero Barboni , Barrett Katz , Catherine Vignal Clermont , Laure Blouin , Alfredoa Sadun , Marion Janic , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Jean Fran , Gensight Biologics , Patrick Yu , Valerie Biousse , Valerio Carelli ,